Rapport Therapeutics reports FY2025 net loss $111.5M, RAP-219 Phase 2 positive, Phase 3 Q2 2026

Rapport Therapeutics, Inc.

Net loss Q4 2025 $33.8M, full year $111.5M; R&D expenses $94.8M FY2025 vs $60.9M FY2024.
Cash, equivalents, short-term investments $490.5M at Dec 31, 2025; runway into H2 2029.
RAP-219 Phase 2a in focal onset seizures met primary endpoints: 77.8% median reduction in clinical seizure frequency.
Phase 3 program for RAP-219 in FOS accelerated to Q2 2026; open-label safety trial enrolling.
Entered Tenacia collaboration for Greater China: $20M upfront, up to $308M milestones plus tiered royalties.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Rapport Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2025.

Period: the quarter and year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 10, 2026, Rapport Therapeutics, Inc. (the “Company”) announced its financial results and business highlights for the quarter and year ended December 31, 2025.

View on SEC.gov

310 earnings releases filed in the last 30 days. Browse all earnings releases →

Rapport Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-099336

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.